Medical Oncology Division and Breast Unit

Brindisi, Italy

Medical Oncology Division and Breast Unit

Brindisi, Italy
SEARCH FILTERS
Time filter
Source Type

Lorusso V.,Instituto Tumori Giovanni Paolo II | Cinieri S.,Medical Oncology Division and Breast Unit | Latorre A.,Instituto Tumori Giovanni Paolo II | Porcu L.,Irrcs Instituto Of Ricerche Farmacologiche Mario Negri | And 3 more authors.
Future Oncology | Year: 2017

Aim: Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancer patients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancer patients. Patients & methods: In this subanalysis of the ESEMPIO study database, we selected 91 subjects with well-defined taxane refractoriness and complete data available. Results: 41 patients (45.2%) showed clinical benefit; one complete response (2.2%) and 16 partial responses (17.6%) were observed. Median progression-free survival and median overall survival were 3.1 and 11.6 months, respectively. The most experienced adverse event was asthenia/fatigue (58%), followed by neutropenia (30%). The treatment-related toxicity led to eribulin-dose reduction in 19 patients and suspension in nine. Conclusion: This study shows that eribulin is effective and well tolerated also in taxane-refractory patients in clinical practice. © 2017 Future Medicine Ltd.

Loading Medical Oncology Division and Breast Unit collaborators
Loading Medical Oncology Division and Breast Unit collaborators